2010
Breast cancer screening and mortality
DeVita V. Breast cancer screening and mortality. Nature Reviews Clinical Oncology 2010, 7: 65-65. PMID: 20118972, DOI: 10.1038/nrclinonc.2009.232.Peer-Reviewed Original Research
2005
Herceptin: HERalding a new era in breast cancer care but at what cost?
Hutchinson L, DeVita V. Herceptin: HERalding a new era in breast cancer care but at what cost? Nature Reviews Clinical Oncology 2005, 2: 595-595. PMID: 16341094, DOI: 10.1038/ncponc0378.Peer-Reviewed Original ResearchTreatment Utopia
DeVita V. Treatment Utopia. Nature Reviews Clinical Oncology 2005, 2: 59-59. PMID: 16264858, DOI: 10.1038/ncponc0083.Peer-Reviewed Original Research
1993
Dose Intensity
SURBONE A, DeVITA V. Dose Intensity. Annals Of The New York Academy Of Sciences 1993, 698: 279-288. PMID: 8279768, DOI: 10.1111/j.1749-6632.1993.tb17219.x.Peer-Reviewed Original Research
1991
On clinical alerts.
DeVita V. On clinical alerts. Annals Of Internal Medicine 1991, 115: 234-5. PMID: 2058884, DOI: 10.7326/0003-4819-115-3-234_2.Peer-Reviewed Original ResearchThe influence of information on drug resistance on protocol design The Henry Kaplan Memorial Lecture, International Conference on Mulignant Lymphomas, 6–9 June 1990, Lugano, Switzerland
DeVita V. The influence of information on drug resistance on protocol design The Henry Kaplan Memorial Lecture, International Conference on Mulignant Lymphomas, 6–9 June 1990, Lugano, Switzerland. Annals Of Oncology 1991, 2: 93-106. PMID: 2054322, DOI: 10.1093/oxfordjournals.annonc.a057892.Peer-Reviewed Original ResearchIs a mechanism such as the NCI's Clinical Alert ever an appropriate alternative to journal peer review?
DeVita V. Is a mechanism such as the NCI's Clinical Alert ever an appropriate alternative to journal peer review? Important Advances In Oncology 1991, 241-54. PMID: 1869279.Peer-Reviewed Original ResearchConceptsJournal peer review systemTraditional peer reviewJournal peer reviewNational research enterpriseClinical alertsPeer review systemNational Cancer Advisory BoardPeer reviewPublication of scientific worksCommunicating informationReview systemAcademic toolsAlertsPracticing physiciansAdvisory boardPhysiciansDecision-making processInformationColon cancerClinicStages of colon cancerResearch enterpriseAcademic advancementAdjuvant drug therapy
1990
Primary Chemotherapy Can Avoid Mastectomy, but There Is More to It Than That
DeVita V. Primary Chemotherapy Can Avoid Mastectomy, but There Is More to It Than That. Journal Of The National Cancer Institute 1990, 82: 1528-1528. PMID: 2205725, DOI: 10.1093/jnci/82.19.1528.Peer-Reviewed Original Research
1989
NCI's breast cancer clinical alert: rationale and results.
DeVita V, Hubbard S. NCI's breast cancer clinical alert: rationale and results. Resident & Staff Physician 1989, 35: 49-55. PMID: 10303742.Peer-Reviewed Original ResearchBreast Cancer Therapy: Exercising All Our Options
DeVita V. Breast Cancer Therapy: Exercising All Our Options. New England Journal Of Medicine 1989, 320: 527-529. PMID: 2915656, DOI: 10.1056/nejm198902233200812.Peer-Reviewed Original Research
1986
Dose-response is alive and well.
DeVita V. Dose-response is alive and well. Journal Of Clinical Oncology 1986, 4: 1157-9. PMID: 3525764, DOI: 10.1200/jco.1986.4.8.1157.Peer-Reviewed Original ResearchThe effect of combined modality therapy on local control and survival
DeVita V, Lippman M, Hubbard S, Ihde D, Rosenberg S. The effect of combined modality therapy on local control and survival. International Journal Of Radiation Oncology • Biology • Physics 1986, 12: 487-501. PMID: 3009367, DOI: 10.1016/0360-3016(86)90056-8.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsAnus NeoplasmsBreast NeoplasmsCarcinoma, Small CellClinical Trials as TopicCombined Modality TherapyFemaleHumansKidney NeoplasmsLung NeoplasmsLymphomaNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasmsPrognosisSarcomaSoft Tissue NeoplasmsWilms TumorConceptsLocal controlSystemic treatmentTumor typesPresence of micrometastasesEffective systemic therapyTumor cell numberLocal control measuresModality therapySystemic therapyCommon cancerMetastatic cancerLESS surgeryRadiation therapyTherapeutic programMetastatic processMicrometastasesTherapySurvivalSystemic componentCell numberTumorsMetastasis genesCancerSubstantial numberInverse relationship
1983
Progress in cancer management. Keynote address
Devita V. Progress in cancer management. Keynote address. Cancer 1983, 51: 2401-2409. PMID: 6342749, DOI: 10.1002/1097-0142(19830615)51:12+<2401::aid-cncr2820511302>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsCancer managementUtility of radiotherapyUse of radiotherapyCancer cure ratesWorld War IIEradication of cancerManagement of cancerPrime therapeutic targetFirst chemotherapyNational Cancer ActBlood transfusionLocal recurrenceMedical oncologistsTreatment failureRecurrent cancerCure rateWar IIEffective treatmentTherapeutic targetPatientsRadiotherapySurgerySuch toxicitySerious cancersCancer
1981
Multimodal treatment of primary breast carcinoma Analysis of accomplishments and problem areas
Weiss R, Henney J, DeVita V. Multimodal treatment of primary breast carcinoma Analysis of accomplishments and problem areas. The American Journal Of Medicine 1981, 70: 844-851. PMID: 7011024, DOI: 10.1016/0002-9343(81)90541-6.Peer-Reviewed Original ResearchConceptsAxillary nodesInvolved axillary nodesDisease-free survivalUse of chemotherapyBreast carcinoma patientsCertain patient groupsFuture clinical trialsPrimary breast carcinomaBetter therapeutic indexMurine tumor modelsCarcinoma patientsDrug regimensMultimodal treatmentPatient groupClinical trialsBreast carcinomaBreast cancerTherapeutic indexChemotherapy modePatientsSpecific subgroupsTumor modelMastectomyChemotherapyHuman subjectsResolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma
Broder S, Callihan T, Jaffe E, DeVita V, Strober W, Bartter F, Waldmann T. Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma. Gastroenterology 1981, 80: 166-168. PMID: 7450403, DOI: 10.1016/0016-5085(81)90208-0.Peer-Reviewed Original ResearchConceptsIntestinal lymphangiectasiaCombination chemotherapyMalignant lymphomaUndifferentiated malignant lymphomaSystemic combination chemotherapyGastrointestinal protein lossProtein lossB-cell originSerum protein concentrationMonoclonal B-cell originGastrointestinal symptomsRecurrent vomitingMassive edemaIntestinal lymphangiectasisIntestinal lymphaticsGastrointestinal tractNeoplastic cellsPatientsLymphomaLymphangiectasiaInitial evaluationYr durationChemotherapyEdemaDisease
1980
The evolution of primary multimodality treatment in resectable breast cancer
Henney J, Devita V. The evolution of primary multimodality treatment in resectable breast cancer. Cancer 1980, 46: 999-1008. PMID: 6994877, DOI: 10.1002/1097-0142(19800815)46:4+<999::aid-cncr2820461325>3.0.co;2-e.Peer-Reviewed Original ResearchConceptsDisease-free intervalPremenopausal womenClinical trialsBreast cancerProspective randomized clinical trialsStage II breast cancerAdjuvant therapy studiesResectable breast cancerRandomized clinical trialsNational Cancer InstitutePositive resultsPostmenopausal womenMultimodality treatmentPostoperative periodPrognostic factorsNational mortalityClinical dataEstrogen receptorDrug doseCancer InstituteStage IClinical researchPatientsTherapy studiesTrialsCancer, the Curable Diseases
DeVita V, Kershner L. Cancer, the Curable Diseases. Journal Of The American Pharmacists Association 1980, 20: 16-22. PMID: 6155779, DOI: 10.1016/s0160-3450(15)32990-1.Peer-Reviewed Original ResearchAdvances in the multimodal primary management of cancer.
DeVita V, Henney J, Weiss R. Advances in the multimodal primary management of cancer. Advances In Internal Medicine 1980, 26: 115-29. PMID: 7013437.Peer-Reviewed Original Research
1979
Human models of human diseases; breast cancer and the lymphomas
Devita V. Human models of human diseases; breast cancer and the lymphomas. International Journal Of Radiation Oncology • Biology • Physics 1979, 5: 1855-1867. PMID: 393666, DOI: 10.1016/0360-3016(79)90571-6.Peer-Reviewed Original ResearchThe dilemma regarding postoperative chemotherapy in primary carcinoma of the colon.
Weiss R, DeVita V. The dilemma regarding postoperative chemotherapy in primary carcinoma of the colon. Journal Of The American College Of Surgeons 1979, 149: 267-71. PMID: 380029.Peer-Reviewed Original Research